Bot Detector
IJPC Seal
Download FREE Sample Issue or Article
LEARN MORE
Subscribe Today
A subscription to IJPC provides on-line access to full-text, full-color, printable PDF copies of your subscribed issues, individual articles, and purchased archives.

Penfluridol, a Unique Psychiatric Medicine for the Treatment of Chronic Schizophrenia

Author(s):  Zur Eyal

Issue:  Mar/Apr 2019 - Volume 23, Number 2
View All Articles in Issue

Page(s):  113-119

Penfluridol, a Unique Psychiatric Medicine for the Treatment of Chronic Schizophrenia Page 1
Penfluridol, a Unique Psychiatric Medicine for the Treatment of Chronic Schizophrenia Page 2
Penfluridol, a Unique Psychiatric Medicine for the Treatment of Chronic Schizophrenia Page 3
Penfluridol, a Unique Psychiatric Medicine for the Treatment of Chronic Schizophrenia Page 4
Penfluridol, a Unique Psychiatric Medicine for the Treatment of Chronic Schizophrenia Page 5
Penfluridol, a Unique Psychiatric Medicine for the Treatment of Chronic Schizophrenia Page 6
Penfluridol, a Unique Psychiatric Medicine for the Treatment of Chronic Schizophrenia Page 7

Download in electronic PDF format for $75

Abstract:  Schizophrenia is a serious, disabling, enduring, and relapsing mental illness which causes problems with the ability to think, feel, and perceive things clearly. One cause of relapse and readmission to a hospital is poor compliance with antipsychotic medication, often due to its adverse effects. Schizophrenia may also affect a person’s insight, interfering with their ability to appreciate the benefit of taking medication long term. The relapse rate is significantly higher in those who have discontinued antipsychotic medication. Penfluridol is an unusual, potent, long-acting, first-generation, oral antipsychotic agent indicated for the treatment of chronic schizophrenia, acute psychosis, and Tourette syndrome. It may be considered a depot medication, as it is administered once a week. Despite this positive analysis, and the unique added value of this medication to psychotic, non-compliant patients, Janssen-Cilag, the sole manufacturer of penfluridol worldwide, decided to stop production in 2009. This decision forced many psychotic patients worldwide to abandon the once-a-week convenient treatment and to replace it with a daily, oral treatment or a depot injection. Because penfluridol is no longer commercially available, it has created an opportunity for compounding pharmacists worldwide to accept this challenge and offer this medication to psychiatrists because of its clinical therapeutics. For the past 5 years, penfluridol has been available to compounding pharmacists in Israel and has received favorable feedback from physicians and patients.

Related Keywords: Eyal Zur, BSc Pharm, RPh, MBA, penfluridol, formulations, diphenylbutylpiperidine, chronic schizophrenia, antipsychotic agents, acute psychosis, Tourette syndrome, psychiatric disorders, postsynaptic dopamine receptor, mesolimbic dopaminergic system, neuroleptic adverse effects, drug interactions, herbal supplements, depot administration

Related Categories: FORMULATIONS, MENTAL HEALTH, DOSAGE FORMS/DRUG CARRIERS, NEUROLOGY

Printer-Friendly Version



Related Articles from IJPC
Title/Author
(Click for Abstract / Details / Purchase)
Issue/​Page
View/Buy
Penfluridol, a Unique Psychiatric Medicine for the Treatment of Chronic Schizophrenia
Zur Eyal
Mar/Apr 2019
Pg. 113-119

Drug Therapy for Acute and Chronic Pain in the Cat
Lascelles B Duncan
Sep/Oct 2002
Pg. 338-343

Wetting and/or Solubilizing Agents, Featured Excipient:
Allen Loyd V Jr
Jul/Aug 2001
Pg. 310-312

Sensitization Therapy for Warts
Kuntz Rachael
Jul/Aug 2003
Pg. 266-270

PostScription: Treatment of Chronic Pain with Methadone or Levorphanol
McNulty Jack P
Mar/Apr 2006
Pg. 159-160

Compounding for the Treatment of COVID-19 and Long COVID, Part 4: The Legacy of Chronic COVID
Riepl Mike
, Kaiser Joe
Jul/Aug 2023
Pg. 284-293

A Compendium of Compounding Agents and Formulations, Part 6: Additional Preparations for Refractory Dermal-wound Healing
Riepl Mike
Nov/Dec 2022
Pg. 480-488

Levorphanol, Methadone, and the Management of Intractable Chronic Pain: An Interview with Kerry Schmidt, BA, MBA; Jack P. McNulty, MD, FACP; and George B. Muller, RPh
Vail Jane
Jan/Feb 2006
Pg. 9-11

Aripiprazole 1 mg/mL in Oral-Plus:Ora-Sweet (1:1) Oral Suspension
Allen Loyd V Jr
Jul/Aug 2019
Pg. 314

Treatment of Dermatologic Adverse Events Induced by Oncological Treatments Using Compounded Medications
Zur Eyal
Nov/Dec 2018
Pg. 446-454

Haloperidol 0.5-mg/mL in SyrSpend SF pH4
Allen Loyd V Jr
Sep/Oct 2021
Pg. 417

Using Compounded Medications for the Topical Treatment of Complex Regional Pain Syndrome Type I Following Trauma: A Case Report
Zur Eyal
Jan/Feb 2014
Pg. 14-19

Haloperidol 5-mg/mL Injection
Allen Loyd V Jr
Nov/Dec 2017
Pg. 493

Stability of Compounded Diltiazem Hydrochloride in Cream, Ointment, and Gel Formulations for Topical Use
Teimouri Arezou
, Yeung Pollen, Agu Remigius U
Nov/Dec 2020
Pg. 482-490

Basics of Compounding for Raynaud's Disease
Glasnapp Andrew
Jul/Aug 2003
Pg. 288-291

Compounding for Patients with Polycystic Ovarian Syndrome (Stein-Leventhal Syndrome)
Riepl Mike
May/Jun 2019
Pg. 192-199

Equine Cushing’s Syndrome
Vail Jane
Jan/Feb 2003
Pg. 27-29

Compounded Pimobendan for Canine Chronic Degenerative Mitral Valve Disease and Pulmonary Hypertension
Helms Scott R
, Fox Samantha, Mixon William, Vail Jane
Jan/Feb 2012
Pg. 34-41

Conservative Management of Chronic Kidney Disease in Cats: Recommendations for Veterinarians and Compounding Pharmacists
Meadows Richard L
, Muller George
Sep/Oct 2010
Pg. 382-394

Topical Treatment of Primary Focal Hyperhidrosis, Part 2
Zur Eyal
Mar/Apr 2019
Pg. 94-104

Return to Top